Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Grzegorz S. Nowakowski,Fangxin Hong,David W. Scott,William R. Macon,Rebecca L. King,Thomas M. Habermann,Nina D. Wagner-Johnston,Carla Casulo,James L. Wade,Gauri G. Nagargoje,Christopher M. Reynolds,Jonathon B. Cohen,Nadia Khan,Jennifer E. Amengual,Kristy L. Richards,Richard F. Little,John P. Leonard,Jonathan W. Friedberg,Lale Kostakoglu,Brad S. Kahl,Thomas E. Witzig

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

2021

PURPOSELenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising ...

Keywords:

Lymphoma
Medicine
Prednisone
Vincristine
Diffuse large B-cell lymphoma
Doxorubicin
Oncology
Lenalidomide
Rituximab
Cyclophosphamide
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations